Overview

Ostarine, also known as MK 2866, is a selective androgen receptor modulator (SARM) that has gained attention for its potential in enhancing athletic performance and aiding in conditions like involuntary weight loss due to illness and breast cancer.

Clinical Efficacy

Enobosarm (also called ostarine) is a non-steroidal, orally bio-available and a selective androgen receptor modulator (SARM). It has shown a dose-dependent improvement in total lean body mass and physical function in healthy elderly men and postmenopausal women. Besides this, enobosarm is also useful in the prevention of muscle wasting associated with cancer cachexia. Data from Phase II clinical trial where cancer patients were administrated with ostartine showed improvement in muscle performance (measured by stair climb) and insulin resistance without any visible side effect and toxicity. Hence enobosarm possesses a strong efficacy and safety in cancer cachexia conditions to regulate muscle loss.¹

Ostarine is excreted in urine mainly as the unmodified parent compound or as its glucuronide-conjugated phase-II Metabolite, whereas the abundance of the O-dephenyl-ostarine Metabolite is very low when compared to the parent drug. Furthermore, since O-dephenyl-ostarine could also be present in urine Samples as a contaminant/impurity and/or minor Metabolite of bicalutamide, this Metabolite shall not be considered as the sole criterion for the reporting of an Adverse Analytical Finding for ostarine.